Now I have all the information I need. Let me produce the final consolidated review.

## Summary

PharmaVQA proposes a molecular representation learning framework that uses Visual Question Answering (VQA) — specifically, text questions about pharmacophore properties processed through a Bilinear Attention Network (BAN) over molecular graph features — to produce pharmacophore-aware representations that improve downstream property prediction and ligand discovery. The method is evaluated on 46 benchmarks (Li's property prediction, MoleculeACE, BindingDB DTI) and demonstrated on three ligand targets (HPK1, FGFR1, VIM-1).

## Strengths

- **Novel application of text-conditioned bilinear attention for pharmacophore-guided molecular representation.** The core idea — using VQA-style questions about pharmacophore properties (e.g., "How many hydrogen bond donors?") to condition molecular graph representations via BAN — is a genuinely novel combination. The attention maps provide a natural mechanism for interpretability by showing which text tokens are attended to for which pharmacophore queries, as demonstrated in the donor case study (Section 5.6, Figure 3).

- **Broad empirical evaluation across 46 datasets.** The paper evaluates on Li's 11 property prediction tasks, MoleculeACE (30 regression bioactivity datasets), and BindingDB classification/regression DTI tasks. This is a substantial evaluation scope that covers classification, regression, and interaction prediction.

- **Ligand discovery demonstration with literature-based confirmation.** On three ligand datasets (HPK1, FGFR1, VIM-1), PharmaVQA's Top-20 predictions yielded 10, 15, and 16 molecules respectively that are confirmed in literature/DrugBank as ligands, including 6 HPK1 and 4 FGFR1 ligands not found by the KPGT baseline (Section 5.5). This demonstrates practical utility in drug screening.

- **Interpretability via BAN attention maps.** The case study (Section 5.6, Figure 3) shows that the model assigns high attention weights to semantically relevant text tokens (e.g., "hydrogen", "bond", "donors") when answering donor-related pharmacophore questions, providing a form of explanation that black-box molecular encoders lack.

## Weaknesses

### Fatal

None.

### Major

1. **"Retrieval-augmented" framing is misleading.** The title, abstract, and introduction describe PharmaVQA as a "retrieval-augmented" framework that "retrieves pharmacophore-related information directly from molecule databases." In reality, the method does no external retrieval. The BAN module processes the molecular graph representation and question embeddings through learned attention — this is text-conditioned feature extraction from the molecular graph itself, not retrieval from any external database or knowledge base. The "knowledge prompts" (Section 4.4) are learned feature vectors concatenated with graph encoder outputs. This is multi-task representation learning with text-conditional attention, not retrieval augmentation. Since "retrieval-augmented" is in the title and central to the claimed contribution, this is a significant mischaracterization that overstates what the method does.

2. **The "experimentally validated/confirmed" claims for ligand discovery are overstated.** The paper uses the phrases "experimentally confirmed as potential ligands" (contributions, line 22) and "experimentally validated as potential ligands" (abstract, line 4). However, Section 5.5 describes literature-based confirmation: the predicted molecules were found by "searching for supporting evidence" in published literature and DrugBank (lines 199-201). The conclusions (line 214) are more honest: "confirmed by literature reports." No wet-lab experiments were conducted. The comparison with KPGT is also anecdotal — different screening libraries and validation protocols are used, yet the paper presents the numbers as a direct head-to-head comparison. The paper should clearly distinguish literature-confirmed hits from experimentally validated hits and avoid language that implies new experimental verification.

3. **No ablation studies.** The model has multiple interacting components: the graph encoder, SciBERT, BAN with multiple glimpses, a pharmacophore prediction loss (L_ph), an alignment loss (L_align), and a second graph encoder (Encoder_g') whose relationship to the first is unspecified. There are no ablations that isolate the contribution of any component. We cannot tell whether the VQA-style training adds value beyond a simpler multi-task approach (e.g., directly predicting pharmacophore counts from graph features without text-conditioned attention), whether the alignment loss helps, or whether both graph encoders are needed. Given the complexity of the design, this is a serious gap that undermines the ability to interpret the reported results.

### Minor

4. **No statistical significance analysis across the full benchmark.** While Table 2 reports mean and standard deviation over 3 runs for Li's regression datasets, the paper reports no significance tests (e.g., Wilcoxon signed-rank across the 46 tasks) for the claimed "superior performance" over baselines. For a paper staking its contribution on empirical superiority across many datasets, the reader needs to know whether the improvements are consistent and significant or driven by a few favorable comparisons.

5. **The "prompts" terminology is imprecise.** Section 4.4 describes integrating pharmacophore features "as prompts into the molecular embeddings," but the integration is simple concatenation followed by an MLP (Eq. 13: `concat(f, H_G')`). This is feature concatenation, not prompting in the sense of conditioning a generative model. The paper would be clearer using "auxiliary features" or "text-conditioned representations" instead of "prompts."

6. **Question design is not justified or ablated.** Seven pharmacophores are chosen, each with one or two questions, but there is no justification for why these specific pharmacophores or question phrasings were selected, and no ablation showing the impact of question count or phrasing on downstream performance.

7. **Training details are incomplete.** The paper does not specify: (a) whether SciBERT is frozen or fine-tuned; (b) whether the two graph encoders (Encoder_g and Encoder_g') share weights or are separate; (c) hyperparameters (learning rate, batch size, optimizer, epochs, GPU hardware, training time); (d) the values of the loss balancing hyperparameters α and β (Eq. 12). These omissions make the results hard to reproduce.

8. **Alignment loss construction is underspecified.** The matrix O in Eq. 11 requires node-level functional group membership labels for each pharmacophore type. The paper does not explain how this mapping is obtained — e.g., how donor atoms are identified at the node level, how overlapping functional group memberships are handled.

9. **Interpretability analysis is purely qualitative.** The case study (Section 5.6) shows one molecule with highlighted attention weights on text tokens. No quantitative metric is reported (e.g., average attention weight on known relevant tokens across a test set, or precision@k for token relevance).

10. **The VIM-1 claim is ambiguous.** The paper states "16 of the Top-20 molecules interacting with zinc ion-binding proteins" (line 201). Since VIM-1 is a zinc-binding protein and the screening set is DrugBank, many molecules binding zinc-related proteins may be trivially known. The paper does not report what fraction of DrugBank molecules bind zinc-binding proteins, making this number uninterpretable without a baseline rate.

### Trivial

None.

## Nice-to-Haves

- An ablation comparing PharmaVQA against a simpler baseline that predicts pharmacophore counts directly from graph features without text-conditioned attention, to isolate the value of the VQA framing.
- Reporting the fraction of DrugBank molecules that are known zinc-binding ligands, to contextualize the VIM-1 result.
- Quantitative evaluation of attention interpretability (e.g., mean attention weight on ground-truth pharmacophoric atoms).

## Removed Points

These points were raised in the reviews but are removed for the following reasons:

- **Tables not visible in extracted text**: The tables are image-based and missing due to parser extraction artifacts. The original submission contains them. Removed per policy (formatting artifacts are not author errors).
- **Missing related works / comparison table**: Per policy, missing related works cannot be confirmed without external sources and are not included.
- **"The method is not VQA, it's just regression"**: The paper's VQA framing is legitimate — questions about molecular properties with numerical answers is a valid VQA formulation (VQA does not require generative text output). The non-standard use of "retrieval" is the real framing issue, not the VQA framing itself.
- **"The paper should cover additional domains/tasks"**: These would turn the paper into a different, broader paper. The current scope is defensible.
- **Generic formatting/style nitpicks**: Removed per policy.

## Novel Insights

Beyond the paper's own contributions, the reviews surface a meta-observation: the paper's core technical contribution — using text-conditioned attention to extract pharmacophore information from molecular graphs as an auxiliary task — is actually a promising direction that is obscured by the inflated "retrieval-augmented" branding. The idea of querying a molecular graph with natural language questions about functional groups and using the attention patterns to guide downstream representations is more novel than the "retrieval" framing suggests. The reviews also highlight that the community's expectations for representation learning papers are changing: ablation studies and significance testing are no longer optional, and claims of "experimental validation" are scrutinized carefully.

## Suggestions

1. **Reframe the contribution honestly.** Replace "retrieval-augmented" with "text-conditioned attention" or "VQA-guided" throughout. The method does not retrieve from external databases — it uses question-conditioned attention on the molecular graph. The title should reflect what the method actually does.

2. **Replace "experimentally validated" with "literature-confirmed" or "previously reported"** for the ligand discovery claims. Add a clear statement about the validation protocol.

3. **Add ablation studies** that isolate the effect of (a) the pharmacophore prediction loss L_ph, (b) the alignment loss L_align, (c) the VQA questions vs. direct pharmacophore count prediction, and (d) the two-encoder design.

4. **Disclose training details** including hyperparameters, whether SciBERT is frozen, the relationship between Encoder_g and Encoder_g' (shared or separate weights), hardware, and training time.

5. **Run significance tests** (e.g., Wilcoxon signed-rank) across the 46 tasks comparing PharmaVQA to the strongest baseline, and report the number of tasks where improvements are positive.

6. **Explain how node-level functional group labels (matrix O) are obtained** for the alignment loss.

## Score and Decision

MY FINAL SCORE: <pineapple>4.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>